Track topics on Twitter Track topics that are important to you
Cotinga Pharmaceuticals (TSXV:COT) has announced its financial and operating results for Q4 and full year ended April 30, 2018. As quoted in the press release: Advanced the clinical development of COTI-2: In March 2018, Cotinga submitted an updated clinical package to regulatory authorities to expand its ongoing clinical trial of COTI-2. The protocol amendment expanded … ContinuedNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...